For research use only. Not for therapeutic Use.
Formoterol (Cat No.:I004530) is a highly selective β2-adrenergic agonist, known for its bronchodilator properties. It acts specifically on the β2-adrenergic receptors in the lungs, resulting in relaxation of the smooth muscles and improved airflow. Formoterol is commonly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Its selective β2 receptor activity makes it a favorable choice for managing respiratory conditions. Additionally, research suggests that formoterol may have potential metabolic benefits, although further studies are needed to fully understand its effects in this regard.
| Catalog Number | I004530 |
| CAS Number | 67346-49-0 |
| Synonyms | N-(2-hydroxy-5-(1-hydroxy-2-((1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide |
| Molecular Formula | C19H24N2O4 |
| Purity | ≥95% |
| Target | Adrenergic Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide |
| InChI | InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1 |
| InChIKey | BPZSYCZIITTYBL-YJYMSZOUSA-N |
| SMILES | CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O |
| Reference | </br>1:Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment. Wolthers OD, Moore A, Mersmann S, Dissanayake S.J Aerosol Med Pulm Drug Deliv. 2017 May 16. doi: 10.1089/jamp.2016.1335. [Epub ahead of print] PMID: 28510491 </br>2:A multicenter, cross-sectional, observational study of budesonide/formoterol maintenance and reliever therapy in real-world settings. Lin J, Li J, Yu W, Liu Y, Liu C, Chen P, He H, He B, Liu S, Zhou X.Respir Med. 2017 Jun;127:45-50. doi: 10.1016/j.rmed.2017.04.004. Epub 2017 Apr 6. PMID: 28502418 </br>3:Formoterol and fluticasone propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial epithelial cells exposed to cigarette smoke. Ferraro M, Gjomarkaj M, Siena L, Di Vincenzo S, Pace E.Biochim Biophys Acta. 2017 May 5. pii: S0925-4439(17)30140-0. doi: 10.1016/j.bbadis.2017.05.003. [Epub ahead of print] PMID: 28483577 </br>4:Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O/’Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12. PMID: 28427541 Free Article</br>5:Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. Jenkins CR, Eriksson G, Bateman ED, Reddel HK, Sears MR, Lindberg M, O/’Byrne PM.BMC Pulm Med. 2017 Apr 20;17(1):65. doi: 10.1186/s12890-017-0401-y. PMID: 28427362 Free PMC Article</br>6:Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect. Patel BS, Kugel MJ, Baehring G, Ammit AJ.Pulm Pharmacol Ther. 2017 Apr 13. pii: S1094-5539(16)30187-0. doi: 10.1016/j.pupt.2017.04.006. [Epub ahead of print] PMID: 28414142 </br>7:[Formoterol-budesonide combination for maintenance and relief in children and adolescents with asthma]. de Bilderling G, Smal D, Bradatan E.Rev Med Liege. 2016 Dec;71(12):546-550. Review. French. PMID: 28387094 </br>8:A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, Callan C, McLoughlin A, Woodhead V, Brady A, Juniper EF, Barnes PJ, Price D.J Allergy Clin Immunol Pract. 2017 Mar 25. pii: S2213-2198(17)30093-4. doi: 10.1016/j.jaip.2017.02.006. [Epub ahead of print] PMID: 28351782 </br>9:Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler® dry powder inhaler. Abadelah M, Hazim F, Chrystyn H, Bagherisadeghi G, Rahmoune H, Larhrib H.Eur J Pharm Sci. 2017 Mar 27;104:180-187. doi: 10.1016/j.ejps.2017.03.035. [Epub ahead of print] PMID: 28351669 </br>10:A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. D/’Urzo A, Rennard S, Kerwin E, Donohue JF, Lei A, Molins E, Leselbaum A.Respir Med. 2017 Apr;125:39-48. doi: 10.1016/j.rmed.2017.02.008. Epub 2017 Feb 16. PMID: 28340861 |
